Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-09-08
1999-11-30
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 514 23, 514908, 514918, 514920, 424572, 530350, 530827, 530828, 436 64, A61K 3816, C07K 1400
Patent
active
059942983
ABSTRACT:
The present invention provides the methods to isolate the proteins specifically induced apoptosis (programmed cell death) in prostate cancer cells (LNCAP), leukemia cells (HL-60), and breast cancer cells (MCF-70), but without effect in normal human lung fibroblast cells (CCD 39 Lu). P-1 has no effect on breast cancer cells. Five proteins have been isolated from the conditioned media of culture cells: (1) Apogen P-1: the proteins (Apogen P-1a, Apogen P-1b and Apogen P-1c) isolated from the conditioned medium of XC cells are able to induce apoptosis in prostate cancer cells (LNCAP) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84), breast cancer (MCF-7) and leukemia (HL-60) cells. (2) Apogen P-2: the protein isolated from the conditioned medium of C3H10T1/2 cells is able to induce apoptosis in prostate cancer cells (LNCAP) and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu) and colon cancer (T84) cells. (3) Apogen L: the protein isolated from the conditioned medium of XC cells is able to induce apoptosis in leukemia cells (HL-60), and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84) and prostate cancer (LNCAP) cells. The isolated protein Apogen P-2 is at least in part comprised of bovine fetuin. When properly prepared, fetuin is able to induce apoptosis in leukemia cells (HL-60), prostate cancer (LNCaP and PC-3) cells, colon cancer (Colo 205) cells, breast cancer (MCF-7) cells, and lung cancer (Calu-1) cells. The invention may lead to the discovery of a novel class of anticancer drug that aims at prostate cancer, breast cancer, leukemia and other cancers by inducing apoptosis in cancer cells without affecting normal cells.
REFERENCES:
patent: 5449757 (1995-09-01), Serrero
patent: 5639727 (1997-06-01), Little et al.
Wang et al., Oncogene, vol. 15 pp. 143-157, Sep. 1997.
Yang, et al., "Human a.sub.2 -HS-glycoprotein/bovine fetuin homologue identification and development regulation of the gene", Biochemica et Biophysica Acta 1130 (1992) 149-156.
Yoshioka, et al., "The Complete Amino Acid Sequence of the A-chain of Human Plasma a.sub.2 HS-glycoprotein", The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1665-1676 (1986).
Gejyo, et al., "Characterization of the B-Chain of Human Plasma a.sub.2 HS-Glycoprotein", The Journal of Biological Chemistry, vol. 258 No. 8, pp. 4966-4971 (1983).
von Bulow, et al., "Human fetuin/a.sub.2 HS glycoprotein in colloid and parenchymal cells in human fetal pituitary gland", Histochemistry, (1993) 99:13-22.
Spiro, "Studies on Fetuin, a glycoprotein of Fetal Serum" The Journal of Biological Chemistry, vol. 235, No. 10, pp. 2860-2869.
Grant, et al., "Effects of Epidermal Growth Factor, Fibroblast Growth Factor, and Transforming Growth Factor-B on Cornmeal Cell Chemotaxis", Ivestigative Ophthalmology & Visual Science, vol. 33, No. 12 (1992).
Wiley, et al., "Identification and Characterization of a New Member of the TNF Family That Induces Apoptosis", Immunity vol. 3, 673-682 (1995).
Kawakami, et al., "Cachectin/TNF Kills or Inhibits the Differentiation fo 3T3-L1 Cells According to Developmental Stage", J. of Cellular Physiology, 138:1-7 (1989).
Krammer. et al., "Apoptosis in the APO-1 System", Apoptosis: The Molecular basis of Cell Death, pp. 87-99 (1991).
Lin, et al., "Invitro Apoptosis in the Human Hepatoma Cell Line Induced by Transforming Growth FActor B.sub.1 ", Cancer Research, 52, 385-388 (1992).
Grotendorst, et al., "Attachment of smoth muscle cells to collagen and their migration toward platelet-derived growth factor", Proc. Natl. Acad. Sci. USA, vol. 78, No. 6, pp. 3669-3672 (1991).
Tsai David
Yu Jenny
Celsa Bennett
Kohies Katharine H.
Trojan R. Joseph
LandOfFree
Proteins for cancer cell specific induction of apoptosis and met does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteins for cancer cell specific induction of apoptosis and met, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteins for cancer cell specific induction of apoptosis and met will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672483